Our data demonstrates that positive rates of PD-L1 expression (CPS ≥ 1) are lower in CDH1-MT patients than in CDH1-WT patients, indicating that CDH1-MT GC patients might not benefit from immunotherapy. The gene discussed is CDH1; the disease is gastric cancer.